Cancer Medicine is an open access, interdisciplinary oncology journal providing rapid publication of research from global biomedical researchers across the cancer sciences. Indexed in Medline and Web of Science, we cover the breadth of oncology: clinical cancer research, cancer biology, cancer prevention, and bioinformatics.

Journal Metrics

  • 5CiteScore
  • 3.1Journal Impact Factor
  • 15%Acceptance rate
  • 9 days Submission to first decision
view all metrics

Reasons to submit your manuscript to Cancer Medicine:

  • High standard, rigorous peer review
  • International Editorial Board
  • Indexed in Medline and Web of Science
  • Rapid publication
  • Open access and fully compliant with open access mandates
  • Authors retain copyright
  • Wiley's tradition in publishing excellence

Cancer Medicine is a peer-reviewed Wiley Open Access journal publishing quality research with speed and efficiency. For further information, visit the Wiley Open Access website.

On the Cover

Skip slideshow
Cover Image
The cover image is based on the article Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models by Syeda Afshan et al., https://doi.org/10.1002/cam4.70240.
Cover Image
The cover image is based on the article Lymph node metastasis in early invasive lung adenocarcinoma: Prediction model establishment and validation based on genomic profiling and clinicopathologic characteristics by Wei Guo et al., https://doi.org/10.1002/cam4.70039.
Cover Image
The cover image is based on the Research Article Exosome-related lncRNA score: A value-based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma by Zhan Yang et al., https://doi.org/10.1002/cam4.7308.
Cover Image
The cover image is based on the Research Article Clinical Analysis of EV-Fingerprint to Predict Grade Group 3 and Above Prostate Cancer and Avoid Prostate Biopsy by Adrian Fairey et al., https://doi.org/10.1002/cam4.6216.
more >

Articles

RESEARCH ARTICLE
Open access

Rural Cancer Survivors' Perceived Delays in Seeking Medical Attention, Diagnosis and Treatment: Findings From a Large Qualitative Study

Alyssa Taglieri-Sclocchi, Ingrid Bindicsova, Susannah K. Ayre, Michael Ireland, Sonja March, Fiona Crawford-Williams, Suzanne Chambers, Jeff Dunn, Belinda C. Goodwin, Elizabeth A. Johnston, 
  •  21 July 2025
RESEARCH ARTICLE
Open access

Incidence, Mortality and Survival Time Trends of Brain and CNS Tumours in the Canton of Zurich (Switzerland) Between 1980 and 2021

Miriam Wanner, Flurina Suter, Manuela Limam, Dimitri Korol, Sabine Rohrmann, 
  •  21 July 2025
RESEARCH ARTICLE
Open access

Factors Associated With Self‐Report Symptom Screening Adherence in Pediatric Cancer Patients

L. Lee Dupuis, Emily Vettese, Catherine Aftandilian, Vibhuti Agarwal, Christina Baggott, Scott M. Bradfield, Nicole Crellin-Parsons, David R. Freyer, Kara M. Kelly, Allison A. King, Wade Kyono, Ramamoorthy Nagasubramanian, Etan Orgel, Michael E. Roth, Farha Sherani, Lolie Yu, Allison C. Grimes, Melissa P. Beauchemin, Lisa M. Klesges, George A. Tomlinson, Lillian Sung, 
  •  21 July 2025
REVIEW
Open access

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors

Wenke Li, Menghui Xu, Mo Cheng, Jing Wei, Lin Zhu, Yu Deng, Fukun Guo, Feng Bi, Ming Liu, 
  •  21 July 2025
METHOD
Open access

Feeder Cell Detachment in Drug Response Profiling of Leukemia Cell Coculture Can Be Prevented by Conditioned Medium

Ivana Vonkova, Olga Martinkova, Jitka Stancikova, Ctibor Skuta, Ondrej Hrusak, Petr Bartunek, 
  •  19 July 2025
More articles

Articles with the most citations published in the Last 2 Years according to CrossRef. The citation counts listed reflect the total number of all citations to date.

Open access

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Kamlesh Bisht, Taro Fukao, Marielle Chiron, Paul Richardson, Djordje Atanackovic, Eduardo Chini, Wee Joo Chng, Helgi Van De Velde, Fabio Malavasi, 

Graphical Abstract

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma Issue 20, 2023

Daratumumab and isatuximab are two CD38 targeting antibodies approved for the treatment of multiple myeloma. In this review we summarize the biology of the CD38 target, various assets targeting CD38, mechanism of action of daratumumab and isatuximab and their immunomodulatory properties, resistance mechanisms and approaches to overcome resistance against CD38 antibodies. We also discuss the similarities and differences of the mechanism of action of these two antibodies, which might be important for immune modulation and overcoming immunosuppression in the myeloma bone marrow environment.

Open access

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial

Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya-Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani, 
Open access

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Hossein Javid, Mahsa Akbari Oryani, Nastaran Rezagholinejad, Ali Esparham, Mahboubeh Tajaldini, Mehdi Karimi-Shahri, 
More articles

Recent issues

Latest news

More news >